MedPath

Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction

Phase 3
Active, not recruiting
Conditions
Eczema
Respiratory Tract Infections
Allergy
Interventions
Biological: BCG
Registration Number
NCT01906853
Lead Sponsor
Murdoch Childrens Research Institute
Brief Summary

1. To determine if BCG immunisation at birth, compared to no BCG immunisation, leads to a reduction in measures of allergy and infection in the first 12 months of life.

2. To evaluate the immunological mechanisms underlying the non-specific effects of BCG by comparing markers of immunity between the BCG and non-BCG groups.

Detailed Description

There has been a dramatic rise in allergic diseases worldwide since the 1980s. Asthma rates increased first, followed by eczema, allergic rhinitis and, more recently, food allergy - especially in infants and young children. In Australia, the prevalence of allergic disease is particularly high: up to 30% of children are affected, and eczema and asthma are among the most common chronic diseases of childhood.

Preventing allergic disease by an immunomodulatory intervention early in life would be a major advance with significant implications for individual health and public health resources. Bacillus Calmette-Guérin (BCG) immunisation is a potential intervention with an established safety profile. This vaccine has powerful non-specific effects on the cellular immune response that potentially prime host immunity away from an allergic pathway. Observational data and one small randomised controlled trial (RCT) suggest that BCG immunisation at birth leads to a substantial reduction in allergic disease - however, there is an absence of level 1 evidence.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
1272
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BCGBCGMycobacterium bovis BCG (Bacille Calmette Guérin) vaccine, Danish Strain 1331
Primary Outcome Measures
NameTimeMethod
Lower respiratory tract infection (LRTI)0-12 months

Measured by parent report

Current asthma5 years of age

Using ISAAC definitions

Atopic sensitisation measured by skin prick test (SPT)5 years of age

Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food and aeroallergens

Lower respiratory tract infection (LRTI) hospital admissions0-5 years of age

Proportion of participants with ≥1 hospital admission for LRTI reported by parent

Eczema ever0-5 years of age

Proportion of participants with eczema measured by Williams' UK diagnostic criteria using parental report of symptoms

Asthma ever5 years of age

Using ISAAC definitions

Secondary Outcome Measures
NameTimeMethod
Parent report of food allergy0-5 years of age

Proportion of participants with an allergic reaction to any food reported by parent

Egg sensitisation5 years of age

Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to egg allergen

DiarrhoeaPrior to first DTP vaccination

Proportion of participants with ≥1 episodes of diarrhoea

Eczema ever0-5 years of age

Proportion of participants with eczema measured by a combined eczema measure

Atopic sensitisation to multiple allergens measured by SPT5 years of age

Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to two or more of a panel of food allergens and aeroallergens

Egg allergy5 years of age

Proportion of participants with a challenge-proven egg allergy OR convincing history of egg allergy in participants with a SPT wheal diameter ≥2 mm greater than negative control at 15 min to egg

Clinical food allergy5 years of age

Proportion of participants with challenge-proven food allergy OR convincing history of food allergy in participants with a SPT wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food allergens

Atopic sensitisation measured by SPT using a more stringent cut-off5 years of age

Proportion of participants with a positive SPT defined as wheal diameter ≥3 mm greater than negative control at 15 min to one or more of a panel of food allergens and aeroallergens

Rate of lower respiratory tract infection (LRTI)0-5 years of age

Number of clinical episodes of LRTI, by parental report

Asthma severity2-5 years of age

Hospital admissions for asthma, by parental report

Rate of upper respiratory tract infection (URTI)Prior to first DTP vaccination

Number of clinical episodes of upper respiratory tract infections, by parent report

Rash with feverPrior to first DTP vaccination

Proportion of participants with ≥1 episodes of rash with fever

Eczema0-5 years of age

Proportion of clinician-diagnosed eczema, by parental report

Eczema onset0-5 years of age

Age of onset of eczema, by parental report

Eczema severity0-5 years of age

Eczema medication use, by parental report

Atopic wheeze5 years of age

Proportion of participants with a positive SPT defined as wheal diameter ≥2 mm greater than negative control at 15 min to one or more of a panel of food and aeroallergens together with parent-reported wheeze

Infections0-5 years of age

Hospital admissions for any infection by parental report

Rate of feverPrior to first DTP vaccination

Number of clinical episodes of fever, by parent report

Laboratory measures of the immune responseTime Frame: 0-5 years of age
Lower respiratory tract infection (LRTI)0-5 years of age

Proportion of participants with ≥1 episode of LRTI, by parental report

Hospitalisation for respiratory tract infection (RTI)0-5 years of age

Proportion of participants with ≥1 hospital admission for a RTI, by parent report

Rate of any infectionPrior to first DTP vaccination

Number of clinical episodes of where an infant had symptoms of: wheeze, rattle/rattly chest, fever, runny/blocked nose, cough, or diarrhoea (with vomiting), by parent report

Trial Locations

Locations (2)

Mercy Hospital for Women

🇦🇺

Heidelberg, Victoria, Australia

Royal Children's Hospital

🇦🇺

Melbourne, Victoria, Australia

© Copyright 2025. All Rights Reserved by MedPath